Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels

By Pharmaceutical Processing | December 17, 2010

Bayer HealthCare Pharmaceuticals, Inc. today announced the
FDA has approved a new oral contraceptive (OC), SAFYRALT (drospirenone 3 mg/
ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate
calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL
raises folate levels for the purpose of reducing the risk of rare neural tube
defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing
it. SAFYRAL provides the birth control YASMIN (drospirenone 3 mg/ ethinyl
estradiol 30 mcg)with 451 mcg levomefolate calcium, which is a B vitamin.

SAFYRAL is the second Bayer OC which contains folate. In
September, the FDA approved BeyazT (drospirenone 3 mg/ ethinyl estradiol 20
mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets),
the first OC approved by the FDA to raise folate levels in women who choose an
OC for birth control.

“With the FDA approval of Safyral, Bayer now offers two
oral contraceptives that contain folate,” said Leslie North, Vice
President of Marketing, Women’s HealthCare, Bayer HealthCare Pharmaceuticals.

“SAFYRAL and Beyaz are part of Bayer’s growing women’s
health franchise, and these new products reinforce our commitment to providing
women various contraceptive options.”  

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE